NP Bioinnovation A/S: Financial statements 2024
CVR: 41598263
Source: annual report 2024, Danish Business Authority
01/04/2023 – 31/03/2024
NP Bioinnovation A/S (CVR 41598263) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -59,167 and a net result of DKK -80,271. Equity in the 2024 report amounted to DKK 227,959. The solvency ratio was 86.8%.
- Gross Profit
- DKK -59,167
- Profit/Loss
- DKK -80,271
- Equity
- DKK 227,959
- Total Assets
- DKK 262,645
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 6, 2024, CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB has been appointed auditor of NP Bioinnovation A/S.
As of December 6, 2024, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of NP Bioinnovation A/S.
About NP Bioinnovation A/S
NP Bioinnovation A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named NP Communications A/S and Managementselskabet af 12.08.2020 A/S. The management consists of Christian Torben Hill-Madsen. The board consists of Peter Severin Bach (chair), Allan Traugott Wehnert and Henrik Rouf. The company is owned by Nordicus Partners Corporation. The company has 12 employees (2026). In 2026, the company reported a gross profit of DKK 4,853,562 and a net result of DKK -5,521,565 compared with DKK -60,069 the year before. Equity in the 2026 report amounted to DKK -5,353,675.